CAR (chimeric antigen receptor) T-cell therapy is a promising new
treatment for some of the most challenging cases we face in pediatric acute
lymphoblastic leukemia (ALL). It works by modifying the body's
T-cells, a type of immune system cell that hunts and destroys abnormal cells,
such as cancer cells.
Learn more about CAR T-cell therapy.
Dana-Farber/Boston Children's is a certified treatment
center for providing the FDA-approved CAR T-cell therapy, KYMRIAH, to patients
who are up to 25 years old with second or later relapsed or refractory
B-cell acute lymphoblastic leukemia (ALL).
We are committed to finding the best treatment for our patients.
We evaluate each patient individually to determine a personalized treatment
plan. This may include CAR T-cell therapy, stem cell transplant, clinical
trials, or a combination of these therapies. To determine the best treatment
course for a patient, we evaluate factors including the biology of the patient’s
cancer, the time of relapse, and patient-specific attributes like age. For
example, the best treatment plan for one patient may be using CAR T-cell therapy
as a bridge to a stem cell transplant, and for another, it may be only a stem
answers to frequently asked questions about KYMRIAH and CAR T-cell therapy.
For more information about whether KYMRIAH is right for
your child or to refer a patient, contact:
Colleen Dansereau, RN
Director of Clinical Operations, Gene Therapy Program
After undergoing a promising new treatment for acute lymphoblastic leukemia (ALL), Cole Malone is back to doing what he loves: playing on a flag football team with his twin brother, Michael.